深髓静脉:在阿尔茨海默氏病的临床进展的预测因素
Jianbo Li1,2, Lianyan Xu1,2, Fanlin Liu3
1Department of Radiology, Zhongshan Hospital, Fudan University, Shanghai, China.
Quantitative imaging in medicine and surgery
|January 12, 2026
概括
深髓静脉 (DMVs) 的改变与阿尔茨海默病 (AD) 的进展有关. 增加的DMVs得分预测认知能力下降,为早期AD检测提供了潜在的新成像生物标志物.
科学领域:
- 神经成像是一种神经成像.
- 神经学 神经学
- 生物标志物发现发现
背景情况:
- 由于缺乏可靠的生物标志物,早期发现阿尔茨海默病 (AD) 受到阻碍.
- 深髓静脉 (DMVs) 被认为是神经退行过程的潜在指标.
研究的目的:
- 调查深髓静脉 (DMV) 的变化是否可以预测阿尔茨海默病患者和没有阿尔茨海默病患者的认知衰退.
- 探索DMVs,粉样β (Aβ) 负担和认知状态之间的关系.
主要方法:
- 从开放式访问系列成像研究-3 (OASIS-3) 数据库中对170名参与者的回顾性分析,包括认知正常 (CN),轻度认知障碍 (MCI) 和AD组.
- 在敏感度加权成像 (SWI) 上对DMV的评分和使用Cox比例危险模型的评估.
- 调解分析以确定Aβ负担是否调解DMVs对认知的影响.
主要成果:
- 随着疾病的严重程度 (CN < MCI < AD),DMV的得分显著增加.
- 较高的DMV得分与年龄相关,较低的迷你精神状态检查 (MMSE) 得分,皮质体积减少和Aβ负担增加.
- 在AD患者中,DMV的得分预测了AD患者的认知衰退 (HR=1.13,P=0.014) 与良好的分类性能 (AUC=0.800).
- Aβ负担部分调解了DMV和MMSE得分之间的关联.
结论:
- DMV的变化与阿尔茨海默病的严重程度和进展有关.
- DMVs显示出作为一种新的成像生物标志物的潜力,用于识别患有AD进展风险的个体.
- 这些发现表明,DMVs的改变与阿尔茨海默病的Aβ沉积和认知衰退有关.
相关概念视频
01:26Alzheimer's Disease: Overview
1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K
01:22Alzheimer's Disease: Treatment
801
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
801
01:20Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
282
The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...
282
01:21Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation
343
Clinical manifestationsPeripheral Arterial Disease (PAD) manifests through a range of symptoms, from the characteristic intermittent claudication to atypical presentations and severe complications in advanced stages. Intermittent claudication, a hallmark symptom of PAD, presents as exercise-induced muscle pain that typically resolves within minutes of rest. This pain is reproducible and stems from inadequate blood flow, leading to the accumulation of lactic acid produced during anaerobic...
343
01:21Aneurysm II: Clinical Manifestations and Diagnostic Studies
261
Thoracic, aortic arch and abdominal aneurysms are significant vascular conditions that can present with various clinical manifestations and lead to serious complications. Understanding these manifestations and the appropriate diagnostic studies is essential for effective management and treatment.Thoracic Aortic AneurysmsThoracic aortic aneurysms often remain asymptomatic until they reach a size that impinges on adjacent structures. They typically cause deep, diffuse chest pain that radiates to...
261